Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up after NiCord/CordIn allogeneic cord blood transplantation
2015-004813-26Phase 2Completed
- Sponsor
- Gamida Cell
- Start
- Feb 2016
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of omidubicel and CordIn in hematopoietic malignancies and lymphoma, sponsored by Gamida Cell. Primary endpoint: Clinical outcomes after NiCord/CordIn transplantation. Started Feb 2016; status: completed.
02
Drugs
omidubicelCordIn
03
Conditions
hematopoietic malignancieslymphoma
Beyond the preview
Go deeper on 2015-004813-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004813-26.